TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04206605

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching lanadelumab SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab solution in a PFS for injection.
Study: NCT05111665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Group Therapy (RGT)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Study: NCT03631784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 45 mg/m^2
Description: Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC6
Description: Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy (TRT)
Description: The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy (TRT)
Description: The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC2
Description: Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
Study: NCT01730508

Intervention type: DRUG
Intervention: Pegylated Interferon Alfa (Peginterferon Alfa)
Description: Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
Study: NCT00618410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide, USP
Description: Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal placebo
Study: NCT00585611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin - 40 mg orally daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin - 40 mg orally daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04196075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographis Paniculata
Description: AP as palliative treatment
Study: NCT01610895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions
Description: Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions
Description: Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed.
Study: NCT03199040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -Human monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Description: -The vaccine will be given by the TDS-IM system

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Description: -The vaccine will be given by the TDS-IM system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM system (Inchor Medical Systems)
Description: -At each vaccination time point, patients will receive two injections at separate sites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM system (Inchor Medical Systems)
Description: -At each vaccination time point, patients will receive two injections at separate sites.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
Study: NCT04265716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical L. reeuteri
Description: Tubes with ointment containing L. reuteri DSM17938

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical L. reeuteri
Description: Tubes with ointment containing L. reuteri DSM17938
Study: NCT01252212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS medication adherence
Description: SMS messages to cell phones.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No SMS adherence reminder
Description: In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
Study: NCT03700320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) Migraine Preventive Medication
Description: Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Atogepant tablets taken orally, once daily for 52 weeks.
Study: NCT04251910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual film containing Dexmedetomidine
Description: Sublingual film containing Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual film containing Dexmedetomidine
Description: Sublingual film containing Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual film containing Dexmedetomidine
Description: Sublingual film containing Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual film containing Dexmedetomidine
Description: Sublingual film containing Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo Film
Description: Sublingual placebo film that matches BXCL501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo Film
Description: Sublingual placebo film that matches BXCL501
Study: NCT01709084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
Study: NCT01935778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and capecitabine and oxaliplatin
Description: Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
Study: NCT04251910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo Film
Description: Sublingual placebo film that matches BXCL501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo Film
Description: Sublingual placebo film that matches BXCL501
Study: NCT04303130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days).
Study: NCT03880942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informative story book
Description: Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Informative Story Book
Description: Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
Study: NCT02910947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided quadratus lumborum or Transversus Abdominis plane block
Description: The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided quadratus lumborum or Transversus Abdominis plane block
Description: The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
Study: NCT03300895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Moderate-intensity continuous exercise
Description: 30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
Study: NCT01664988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscular relaxation
Description: muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breath control
Description: breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min

Intervention type: OTHER
Group type: OTHER
Intervention: control (routine care)
Description: received routine care of clinic or health center and use drugs if necessary
Study: NCT04101279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical management of stress urinary incontinence with midurethral tension free tape.
Description: Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.
Description: Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
Study: NCT00589420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT03375398

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice
Description: Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
Study: NCT00243386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Study: NCT02707380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 3 exercises that do not include these 7 muscle-strengthening exercises
Study: NCT04276389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided paclitaxel drug-coated balloon angioplasty
Description: OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angiography-guided paclitaxel drug-coated balloon angioplasty
Description: Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
Study: NCT01637220

Intervention type: BIOLOGICAL
Intervention: Blood volume collected specifically for this study
Description: * case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection
Study: NCT03422432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
Study: NCT03908320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual Cycle Timing
Description: Quit date is set to menstrual phase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menstrual Cycle Timing
Description: Menstrual cycle timing of quit date is monitored

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT Patch
Description: NRT patch is provided

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT Patch
Description: NRT patch is provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation Counseling
Description: Cessation counseling is provided

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Cessation counseling is provided
Study: NCT01450449

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 25 Gy in 5 daily fractions over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 40 Gy in 15 daily fractions over 3 weeks
Study: NCT00966342

Intervention type: DRUG
Group type: OTHER
Intervention: Fluviral 2009/10
Description: single dose given IM .05 mL
Study: NCT04532476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy
Description: Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators.
Study: NCT04267341

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again

Intervention type: OTHER
Intervention: 10 Meter Walk Test
Description: 10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance

Intervention type: OTHER
Intervention: 10 Meter Walk Test
Description: 10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance

Intervention type: OTHER
Intervention: 10 Meter Walk Test
Description: 10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance

Intervention type: OTHER
Intervention: Purdue Pegboard Test
Description: Purdue Pegboard test evaluates the fine manuel dexterity

Intervention type: OTHER
Intervention: Purdue Pegboard Test
Description: Purdue Pegboard test evaluates the fine manuel dexterity

Intervention type: OTHER
Intervention: Purdue Pegboard Test
Description: Purdue Pegboard test evaluates the fine manuel dexterity
Study: NCT02241369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3106, INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3106, INO-9012
Study: NCT01017003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: 0.6mg colchicine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine tablets
Description: 0.6mg q12 hours for 10 days
Study: NCT03426956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Ingestion of glucose (50 g) dissolved in 200 ml water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose + Canagliflozin
Description: Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
Study: NCT00974246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair diskus
Description: Advair diskus 50/250 1 inhalation bid for 16 weeks
Study: NCT04615754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyperketonemia - use of ketone (3-OHB) infusion
Description: The effect of intravenous ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyperketonemia - use of ketone (3-OHB) infusion
Description: The effect of intravenous ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo - use of saline infusion
Description: Saline is infused as an comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo - use of saline infusion
Description: Saline is infused as an comparator
Study: NCT04451577

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, analysis of biological samples

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, analysis of biological samples
Study: NCT00058812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV specific T cells
Description: One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.